{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:13:40Z","timestamp":1788455620831,"version":"build-2803163510"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Ministry of Science and Technology","award":["CMRPG8I0211"],"award-info":[{"award-number":["CMRPG8I0211"]}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>For patients with chronic hepatitis B (CHB), the optimal stopping criteria for entecavir or tenofovir disoproxil fumarate treatment remain unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study recruited CHB patients with levels of hepatitis B surface antigen (HBsAg) &amp;lt;100 IU\/mL at the end of treatment (EOT) from Kaohsiung (n\u200a=\u200a190) and Linkou (n\u200a=\u200a188) Chang Gung Memorial Hospitals for use as development and validation groups, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the development group, 108 patients with HBsAg \u226440 IU\/mL were used for analysis of predictors of HBV relapse and HBsAg loss. Multivariate analysis showed that age, nucleos(t)ide analogue (NA)-experienced status, baseline hepatitis B core-related antigen (HBcrAg) and HBsAg at EOT were associated independently with virological and clinical relapse. An HBsAg level of 20 IU\/mL at EOT was the best cut-off value for minimizing HBV relapse. Patients with EOT HBsAg \u226420 IU\/mL had lower virological and clinical relapse rates and higher HBsAg loss rates than those with EOT HBsAg 21\u201340 IU\/mL and HBsAg 41\u2013100 IU\/mL in the development and validation groups. The virological and clinical relapse rates were very low (5-year rates: 6.5% and 0%, respectively) and HBsAg loss rate was very high (5-year rate: 81.7%) in patients with a combination of baseline HBcrAg \u22644 log U\/mL and EOT HBsAg \u226420 IU\/mL in the development group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A combination of baseline HBcrAg \u22644 log U\/mL and EOT HBsAg level \u226420 IU\/mL might reduce the risk of HBV relapse and increase HBsAg loss rate, and might be helpful for off-NA follow-up strategy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac409","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T16:34:46Z","timestamp":1670430886000},"page":"436-439","source":"Crossref","is-referenced-by-count":11,"title":["Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation"],"prefix":"10.1093","volume":"78","author":[{"given":"Tzu-Ning","family":"Tseng","sequence":"first","affiliation":[{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-1259","authenticated-orcid":false,"given":"Wen-Juei","family":"Jeng","sequence":"additional","affiliation":[{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9172-1967","authenticated-orcid":false,"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"2023020108205775400_dkac409-B1","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","article-title":"Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection","volume":"13","author":"Chen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023020108205775400_dkac409-B2","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off therapy durability of response to entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"2023020108205775400_dkac409-B3","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","article-title":"Associations of HBV genotype B vs C infection with relapse after cessation of entecavir or tenofovir therapy","volume":"18","author":"Chiu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023020108205775400_dkac409-B4","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","article-title":"Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU\/mL","volume":"18","author":"Tseng","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023020108205775400_dkac409-B5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222221","article-title":"Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment","volume":"14","author":"Ma","year":"2019","journal-title":"PLoS One"},{"key":"2023020108205775400_dkac409-B6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/apt.15058","article-title":"Combining hepatitis B core related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk","volume":"49","author":"Hsu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2023020108205775400_dkac409-B7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.hepres.2006.08.005","article-title":"Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection","volume":"36","author":"Shinkai","year":"2006","journal-title":"Hepatol Res"},{"key":"2023020108205775400_dkac409-B8","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023020108205775400_dkac409-B9","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/infdis\/jiab596","article-title":"Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in HBeAg-positive patients","volume":"225","author":"Chen","year":"2022","journal-title":"J Infect Dis"},{"key":"2023020108205775400_dkac409-B10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"2023020108205775400_dkac409-B11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","article-title":"Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load","volume":"40","author":"Kimura","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2023020108205775400_dkac409-B12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/00365521.2018.12027892","article-title":"Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan","volume":"1","author":"Lee","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"2023020108205775400_dkac409-B13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/2\/436\/48957739\/dkac409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/2\/436\/48957739\/dkac409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T19:33:21Z","timestamp":1675280001000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/2\/436\/6880610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,12,7]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac409","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,12,7]]}}}